Harvard Bioscience Deferred Revenue 2011-2026 | HBIO

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Harvard Bioscience

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
3.45 M	3.81 M	4.51 M	3.37 M	4.27 M	3.77 M	3.95 M	4.19 M	633 K	500 K	752 K	655 K	640 K	482 K	483 K	451 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.51 M	451 K	2.24 M

Quarterly Deferred Revenue Harvard Bioscience

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.67 M	2.88 M	3.14 M	3.43 M	3.81 M	3.69 M	4.01 M	4.39 M	4.51 M	4 M	3.84 M	4.12 M	3.37 M	-	-	3.96 M	4.27 M	3.62 M	3.68 M	3.64 M	3.77 M	3.77 M	3.77 M	3.77 M	3.95 M	3.55 M	3.53 M	3.72 M	3.82 M	3.27 M	3.82 M	3.82 M	505 K	505 K	505 K	505 K	500 K	500 K	500 K	500 K	752 K	752 K	752 K	752 K	655 K	655 K	655 K	655 K	640 K	640 K	740 K	640 K	482 K	482 K	482 K	482 K	483 K	483 K	483 K	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.51 M	482 K	2.25 M

Deferred Revenue of other stocks in the Medical instruments industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
The Cooper Companies COO	128 M	$ 60.79	0.68 %	$ 12.1 B	USA
iRhythm Technologies IRTC	4.2 M	$ 115.17	0.88 %	$ 3.69 B	USA
Luminex Corporation LMNX	21.1 M	-	-	$ 1.75 B	USA
ICU Medical ICUI	33.8 M	$ 121.75	-1.01 %	$ 3 B	USA
Repro Med Systems KRMD	125 K	$ 3.89	-2.26 %	$ 180 M	USA
Akers Biosciences, Inc. AKER	59.8 K	-	-9.52 %	$ 20.6 M	USA
Intuitive Surgical ISRG	507 M	$ 426.62	-0.34 %	$ 152 B	USA
LeMaitre Vascular LMAT	552 K	$ 99.14	-0.36 %	$ 2.24 B	USA
Alcon ALC	581 M	$ 64.53	0.8 %	$ 40.4 B	Schweiz
Masimo Corporation MASI	95.5 M	$ 178.4	0.03 %	$ 9.51 B	USA
Antares Pharma, Inc. ATRS	3.94 M	-	-	$ 955 M	USA
Cantel Medical Corp. CMD	26.2 M	-	-1.18 %	$ 3.4 B	USA
CRH Medical Corporation CRHM	26.8 K	-	-	$ 282 M	USA
Hill-Rom Holdings, Inc. HRC	110 M	-	-0.05 %	$ 10.3 B	USA
Ekso Bionics Holdings EKSO	1.73 M	-	-	$ 28.6 M	USA
Envista Holdings Corporation NVST	185 M	$ 23.88	0.13 %	$ 4.01 B	USA
Varian Medical Systems, Inc. VAR	782 M	-	-0.02 %	$ 16.3 B	USA
Haemonetics Corporation HAE	43.3 M	$ 56.86	-0.4 %	$ 2.86 B	USA
STAAR Surgical Company STAA	3.75 M	$ 31.88	-0.42 %	$ 1.58 B	USA
STERIS plc STE	160 M	$ 215.75	-0.17 %	$ 21.3 B	USA
Microbot Medical MBOT	16.8 K	$ 1.92	3.51 %	$ 87.9 M	Israel
Milestone Scientific MLSS	340 K	$ 0.34	-0.15 %	$ 27.9 M	USA
Merit Medical Systems MMSI	572 K	$ 62.51	-0.08 %	$ 3.7 B	USA
West Pharmaceutical Services WST	51.9 M	$ 302.94	0.92 %	$ 21.9 B	USA
Pulse Biosciences PLSE	16 K	$ 24.97	-7.88 %	$ 1.68 B	USA
DENTSPLY SIRONA XRAY	74 M	$ 10.04	-3.6 %	$ 2 B	USA
Retractable Technologies RVP	353 K	$ 0.69	-	$ 20.7 M	USA
Pro-Dex PDEX	202 K	$ 59.29	1.09 %	$ 195 M	USA
Predictive Oncology POAI	144 K	-	-	$ 31.1 M	USA
BioLife Solutions BLFS	195 K	$ 20.77	-1.36 %	$ 992 M	USA
Stereotaxis STXS	5.68 M	$ 1.88	-3.34 %	$ 171 M	USA
Baxter International BAX	141 M	$ 17.56	-1.29 %	$ 9.01 B	USA
ResMed RMD	109 M	$ 204.64	1.03 %	$ 29.9 B	USA
NeuroMetrix NURO	1.96 M	-	5.05 %	$ 9.02 M	USA
AngioDynamics ANGO	200 K	$ 11.01	-0.18 %	$ 450 M	USA
Nephros NEPH	70 K	$ 3.21	-3.94 %	$ 34.1 M	USA
OraSure Technologies OSUR	1.52 M	$ 3.04	3.05 %	$ 223 M	USA
Repligen Corporation RGEN	14.6 M	$ 105.54	2.09 %	$ 5.93 M	USA